Connect with us

Hi, what are you looking for?

Stock

Biogen proposes to buy remaining stake in Sage in $442 million deal

(Reuters) – Drugmaker Biogen (NASDAQ:BIIB) will buy all outstanding shares of Sage Therapeutics that it does not already own for $7.22 apiece, a filing showed on Friday, sending the latter’s stock up 34% in extended trade.

As per the filing, Biogen has a 10.2% stake in Sage Therapeutics. The offer price, representing a 30% premium to the stock’s close on Friday, values Sage’s equity at $441.7 million, according to Reuters calculations.

Biogen has been navigating a slow pick-up in sales for its Alzheimer’s drug Leqembi in the United States after concerns over cost, efficacy and side effects.

Sage, whose shares fell 74.9% last year, abandoned the development of its drug dalzanemdor after multiple trial failures. The company said in November that it will focus on its postpartum depression drug, Zurzuvae, which it developed in partnership with Biogen.

In July, Sage also scrapped the development of another neurological disorder drug it was developing with Biogen.

This post appeared first on investing.com

    You May Also Like

    Latest News

    A group of more than 60 former Democratic and Republican attorneys general sent a new letter to Senate leaders Thursday urging the confirmation of...

    Stock

    Investing.com — RBC Capital Markets in a note dated Thursday has downgraded Swatch Group (SIX:UHR) to an “underperform” rating, citing structural and cyclical challenges...

    Stock

    By Rocky Swift TOKYO (Reuters) -Japan’s Fuji Media said on Monday its chairman and the head of its TV unit would step down immediately...

    Stock

    Investing.com — Universal Music Group (AS:UMG) and Spotify (NYSE:SPOT) have announced a new multi-year deal for recorded music and publishing, the companies announced in...



    Disclaimer: Techreportdiversity.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 Techreportdiversity.com